Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus TORNALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus TORNALATE.
AQUAPHYLLIN vs TORNALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Category C
Category C
Bronchodilator
Bronchodilator